The once-weekly BAFF and APRIL inhibitor cut proteinuria by 42% versus placebo at 36 weeks in the ongoing ORIGIN 3 trial, with confirmatory kidney function results anticipated in Q3 2026.
verifying reliability
No specialized terms available for this topic.